Frequently Asked Questions
The U.S. is expected to dominate the multiple sclerosis market due to its large patient population, advanced healthcare infrastructure, and high adoption of innovative treatments.
North America dominates the multiple sclerosis (MS) market, driven by advanced healthcare infrastructure, high adoption of innovative treatment options, and a strong presence of key pharmaceutical companies.
China is expected to witness the highest CAGR in the multiple sclerosis market, driven by an increasing prevalence of MS, improving healthcare infrastructure, and rising awareness about treatment options.
Factors driving the growth of the multiple sclerosis market include the rising prevalence of MS globally, advancements in disease-modifying therapies, and increased awareness and early diagnosis.
Major challenges in the multiple sclerosis market include the high cost of advanced therapies, which limits accessibility for many patients, and the variability in treatment response among individuals.
